E-selectins on the BM endothelium support homing of CML LSC via CD44 and lead to decreased proliferation of leukemia cells and reduced susceptibility to TKI treatment [68]. The gene discussed is SELE; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.